Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis

被引：2

作者：

Tang, Lingrong ^{[1
]}

Liu, Tingting ^{[2
]}

Chen, Jun ^{[3
]}

Dang, Jun ^{[1
]}

Li, Guang ^{[1
]}

机构：

[1] China Med Univ, Dept Radiat Oncol, Hosp 1, Shenyang, Peoples R China

[2] Anshan Canc Hosp, Dept Radiat Oncol, Anshan, Peoples R China

[3] Shenyang Chest Hosp, Dept Radiat Oncol, Shenyang, Peoples R China

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 06期

关键词：

head and neck squamous cell carcinoma; HPV status; immune-checkpoint inhibitor; network meta-analysis; PD-L1; expression; recurrent or metastatic; standard of care; targeted therapy; SQUAMOUS-CELL CARCINOMA; METASTATIC HEAD; OPEN-LABEL; PHASE-III; RECURRENT; METHOTREXATE; GEFITINIB; GENERATION; NIVOLUMAB; DOCETAXEL;

D O I：

10.2217/imt-2020-0070

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We assessed the efficiency of immune checkpoint inhibitors relative to other systemic therapies in previously treated recurrent/metastatic head and neck cancer. Materials & methods: Relative treatment effects were assessed from eligible randomized controlled trials using Bayesian network meta-analyses. Results: Among 15 trials evaluating 14 treatments, nivolumab achieved the best overall survival (OS) benefit; zalutumumab and buparlisib + paclitaxel provided the best progression-free survival benefit and objective response rate. Buparlisib + paclitaxel and zalutumumab were associated with the best OS rate at 6 and 12 months, respectively; nivolumab yielded the best OS rate at 18-24 months. Conclusion: Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.

引用

页码：541 / 555

页数：15

共 33 条

[11] Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study [J].

Ferris, R. L. ;

Haddad, R. ;

Even, C. ;

Tahara, M. ;

Dvorkin, M. ;

Ciuleanu, T. E. ;

Clement, P. M. ;

Mesia, R. ;

Kutukova, S. ;

Zholudeva, L. ;

Daste, A. ;

Caballero-Daroqui, J. ;

Keam, B. ;

Vynnychenko, I. ;

Lafond, C. ;

Shetty, J. ;

Mann, H. ;

Fan, J. ;

Wildsmith, S. ;

Morsli, N. ;

Fayette, J. ;

Licitra, L. .

ANNALS OF ONCOLOGY, 2020, 31 (07) :942-950

[12] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[13] Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression [J].

Ferris, Robert L. ;

Blumenschein, George, Jr. ;

Fayette, Jerome ;

Guigay, Joel ;

Colevas, A. Dimitrios ;

Licitra, Lisa ;

Harrington, Kevin J. ;

Kasper, Stefan ;

Vokes, Everett E. ;

Even, Caroline ;

Worden, Francis ;

Saba, Nabil F. ;

Iglesias Docampo, Lara Carmen ;

Haddad, Robert ;

Rordorf, Tamara ;

Kiyota, Naomi ;

Tahara, Makoto ;

Lynch, Mark ;

Jayaprakash, Vijayvel ;

Li, Li ;

Gillison, Maura L. .

ORAL ONCOLOGY, 2018, 81 :45-51

[14] Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial [J].

Guo, Y. ;

Ahn, M-J ;

Chan, A. ;

Wang, C-H ;

Kang, J-H ;

Kim, S-B ;

Bello, M. ;

Arora, R. S. ;

Zhang, Q. ;

He, X. ;

Li, P. ;

Dechaphunkul, A. ;

Kumar, V ;

Kamble, K. ;

Li, W. ;

Kandil, A. ;

Cohen, E. E. W. ;

Geng, Y. ;

Zografos, E. ;

Tang, P. Z. .

ANNALS OF ONCOLOGY, 2019, 30 (11) :1831-1839

[15] A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer [J].

Jimeno, Antonio ;

Bauman, Julie E. ;

Weissman, Charles ;

Adkins, Douglas ;

Schnadig, Ian ;

Beauregard, Patrice ;

Bowles, Daniel W. ;

Spira, Alexander ;

Levy, Benjamin ;

Seetharamu, Nagashree ;

Hausman, Diana ;

Walker, Luke ;

Rudin, Charles M. ;

Shirai, Keisuke .

ORAL ONCOLOGY, 2015, 51 (04) :383-388

[16] Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types [J].

Kotsakis, Athanasios ;

Georgoulias, Vassilis .

LANCET ONCOLOGY, 2017, 18 (05) :556-557

[17] Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma [J].

Kushwaha, Vandana Singh ;

Gupta, Seema ;

Husain, Nuzhat ;

Khan, Huma ;

Negi, M. P. S. ;

Jamal, Naseem ;

Ghatak, Ashim .

CANCER BIOLOGY & THERAPY, 2015, 16 (02) :346-351

[18] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial [J].

Machiels, Jean-Pascal ;

Subramanian, Somasundaram ;

Ruzsa, Agnes ;

Repassy, Gabor ;

Lifirenko, Igor ;

Flygare, Annika ;

Sorensen, Per ;

Nielsen, Tina ;

Lisby, Steen ;

Clement, Paul M. J. .

LANCET ONCOLOGY, 2011, 12 (04) :333-343

[19] Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial [J].

Machiels, Jean-Pascal H. ;

Haddad, Robert I. ;

Fayette, Jerome ;

Licitra, Lisa F. ;

Tahara, Makoto ;

Vermorken, Jan B. ;

Clement, Paul M. ;

Gauler, Thomas ;

Cupissol, Didier ;

Jose Grau, Juan ;

Guigay, Joel ;

Caponigro, Francesco ;

de Castro, Gilberto, Jr. ;

Viana, Luciano de Souza ;

Keilholz, Ulrich ;

del Campo, Joseph M. ;

Cong, Xiuyu Julie ;

Ehrnrooth, Eva ;

Cohen, Ezra E. W. .

LANCET ONCOLOGY, 2015, 16 (05) :583-594

[20] Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 [J].

Mehra, Ranee ;

Seiwert, Tanguy Y. ;

Gupta, Shilpa ;

Weiss, Jared ;

Gluck, Iris ;

Eder, Joseph P. ;

Burtness, Barbara ;

Tahara, Makoto ;

Keam, Bhumsuk ;

Kang, Hyunseok ;

Muro, Kei ;

Geva, Ravit ;

Chung, Hyun Cheol ;

Lin, Chia-Chi ;

Aurora-Garg, Deepti ;

Ray, Archana ;

Pathiraja, Kumudu ;

Cheng, Jonathan ;

Chow, Laura Q. M. ;

Haddad, Robert .

BRITISH JOURNAL OF CANCER, 2018, 119 (02) :153-159

← 1 2 3 4 →